



TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:
GSHISHIMA@FULBRIGHT.COM


WRITER'S DIRECT DIAL NUMBER:
512/536-3081

April 15, 2002

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG



RECEIVED

APR 26 2002

TECH CENTER 1600/2900

FILE: UTSH:251US

COPY OF PAPERS ORIGINALLY FILED

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

April 15, 2002

Date

Gina N. Shishima

Commissioner for Patents
Washington, DC 20231

RE: SN 10/021,753 "METHODS AND COMPOSITIONS RELATING TO FORTILIN, AN ANTI-APOPTOTIC MOLECULE, AND MODULATORS OF FORTILIN" – Ken Fujise and Edward T.H. Yeh

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C15).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10110495/GNS.


Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Gina N. Shishima
Reg. No. 45,104

GNS/cmb
Encl: as noted

25155398.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ken Fujise
Edward T.H. Yeh

Serial No.: 10/021,753

Filed: October 30, 2001

For: METHODS AND COMPOSITIONS
RELATING TO FORTILIN, AN ANTI-
APOPTOTIC MOLECULE, AND
MODULATORS OF FORTILIN



COPY OF PAPERS
ORIGINALLY FILED

Group Art Unit: 1632

Examiner: Unknown

Atty. Dkt. No.: UTSH:251US/GNS

RECEIVED

APR 26 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

April 15, 2002

Date

Gina N. Shishima

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10110495/GNS.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 15, 2002

Form PTO-1449 (modified)		Atty. Docket No. UTSH:251US/GNS	Serial No. 10/021,753
List of Patents and Publications f r Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		RECEIVED AUG 26 2002 TECH CENTER 1600/2900	
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent D cuments <i>See Page 1</i>	Other <i>See Page 1</i>

JC8,
APR 23 2002
U.S. PATENT & TRADEMARK OFFICE

COPY OF PAPERS
ORIGINALLY FILED**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Baudet <i>et al.</i> , "Differentially expressed genes in C6.9 glioma cells during vitamin D-induced cell death program," <i>Cell Death Differ.</i> , 5(1):116-125, 1998.
	C2	Chitpatima <i>et al.</i> , "Nucleotide sequence of a major messenger RNA for a 21 kilodalton polypeptide that is under translational control in mouse tumor cells," <i>Nucleic Acids Res.</i> , 16:2350, 1988.
	C3	Chung <i>et al.</i> , "Expression of translationally controlled tumor protein mRNA in human colon cancer," <i>Cancer Lett.</i> , 156:185-190, 2000.
	C4	Fujise <i>et al.</i> , "Regulation of apoptosis and cell cycle progression by MCL1," <i>J Biol Chem.</i> , 275:39458-39465, 2000.
	C5	GenBank Accession Number X16064
	C6	Gross <i>et al.</i> , "cDNA sequence coding for a translationally controlled human tumor protein," <i>Nucleic Acids Res.</i> , 17:8367, 1989.
	C7	Haghishat and Ruben, "Purification of novel calcium binding proteins form Trypanosoma brucei: properties of 22-, 24- and 38-kilodalton proteins," <i>Mol and Biochem Parasitology</i> , 51:99-110, 1992.
	C8	Li <i>et al.</i> , "Characterization of fortillin, a novel antiapoptotic protein," <i>J. Biol. Chem.</i> , 276:47542-47549, 2001.

25113187.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSH:251US/GNS	Serial No. 10/021,753
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		RECEIVED APR 26 2002	
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

TECH CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	MacDonald <i>et al.</i> , "Chromosomal localization ¹ of tumor protein, translationally-controlled 1 (TPT1) encoding the human histamine releasing factor (HRF) to 13q12—q14," <i>Cytogenet Cell Genet</i> , 84:128-129, 1999.
	C10	MacDonald <i>et al.</i> , "Molecular identification of an IgE-dependent histamine-releasing factor," <i>Science</i> , 269:688-690, 1955.
	C11	Moulding <i>et al.</i> , "Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival," <i>Blood</i> 92(7), 2495-2502, 1998.
	C12	Sturzenbaum <i>et al.</i> , "Identification of heavy metal induced changes in the expression patterns of the translationally controlled tumour protein (TCTP) in the earthworm <i>Lumbricus rubellus</i> ," <i>Biochimica et Biophysica Acta</i> , 1398:294-304, 1998.
	C13	Teshima <i>et al.</i> , "Macrophage colony-stimulating factor stimulates synthesis and secretion of a mouse homolog of a human IgE-dependent histamine-releasing factor by macrophages in Vitro and In Vivo," <i>J. Immunology</i> , 161:6356-6366, 1998.
	C14	Thiele <i>et al.</i> , "Expression of the gene and processed pseudogenes encoding the human and rabbit translationally controlled tumour protein (TCTP)," <i>Eur. J. Biochem.</i> , 267:5473-5481, 2000.
	C15	Thiele <i>et al.</i> , "Structure of the promoter and complete sequence of the gene coding for the rabbit translationally controlled tumor protein (TCTP) P23," <i>Eur. J. Biochem.</i> , 257:62-68, 1998.

**COPY OF PAPERS
ORIGINALLY FILED**

25113187.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)